RVRobert Victor

Robert Victor

*This is an algorithmically generated author record based on publicly available information.

Robert Victor has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endocrine, gender dysphoria, and sexual function benefits of gender-affirming bilateral orchiectomy: patient outcomes and surgical technique

    by Jenna Stelmar, Robert Victor, Nance Yuan, Shannon M Smith, Samhita Mallavarapu, Sandeep Sandhu, Maurice M Garcia

    Gender-affirming bilateral orchiectomy (GABO) may be completed as either a standalone procedure (sGABO) or at the same time as gender-affirming vaginoplasty (vGABO). GABO is postulated to decrease gender-affirming hormone therapy (GAHT) dosages and reduce gender dysphoria, but these phenomena are not empirically described in the medical literature. The primary aim of this study was to describe changes in GAHT dosages after sGABO and vGABO. A secondary aim was to assess sGABO patients’ preoperative decision-making priorities and postoperative satisfaction. A retrospective chart review identified 204 patients who completed GABO as either a standalone procedure (64% of patients) or at the same time as vaginoplasty (36%). Patient demographic data, surgical outcomes, and pre- and postoperative GAHT dosage data were recorded. Patients completed an opinion questionnaire to assessed decision-making priorities, as well as postoperative satisfaction and changes in quality-of-life measures. Primary outcomes included pre- and postoperative dosages of estradiol, progesterone, and spironolactone. Secondary outcomes included sGABO patient priorities, satisfaction with sGABO, changes in quality-of-life measures between sGABO and vGABO patients, and sGABO recommendations to future patients. The sGABO and vGABO patients experienced a statistically significant dosage reduction in all three GAHT assessed: estradiol, progesterone, and spironolactone (P < .05). All patients discontinued spironolactone postoperatively. Zero complications related to GABO were recorded for patients in either group. The patient questionnaire revealed that sGABO patients prioritize decreasing endogenous testosterone and reducing their GAHT as most important in their decision to undergo sGABO prior to vaginoplasty. A majority of sGABO patients reported improvement in all nine quality-of-life indices. None of the sGABO patients would recommend against sGABO to a friend who is waiting for vaginoplasty. For patients who are interested in vaginoplasty, sGABO may serve as a more immediate, low-risk, intermediary step that comes with the benefits of GABO, including significant GAHT medication reduction and gender dysphoria relief. This study offers a comprehensive evaluation of the impact of GABO on patients, combining empirical data with subjective patient feedback. Limitations include the retrospective design and the use of unvalidated survey questions. Prevaginoplasty GABO is a viable option to more immediately alleviate gender dysphoria and reduce GAHT medications for patients who are interested in gender-affirming vaginoplasty.


  • Open Access

    A rare case of late onset malignant hyperthermia

    by Govind Rajan, Robert Victor, Richard Kelly, Ryan Cockrill, Karen Katrivesis, Corey Nelson

    A 42-year-old man with neck squamous cell carcinoma underwent awake fiberoptic intubation and tumor resection under general anesthesia. He developed malignant hyperthermia several hours into the surgical procedure. This case highlights malignant hyperthermia’s (MH) variable time course, pathognomonic signs, and the need for rapid diagnosis and treatment. Early recognition and treatment led to rapid resolution of MH. Ongoing discussion of MH is imperative because this disease is often difficult to diagnose early in its time course and may be fatal if not treated expeditiously. Abbreviations: DS - Dantrolene sodium; DSIS - dantrolene sodium injectable suspension; GA - general anesthesia; MH - malignant hyperthermia; EtCO2 - end tidal carbon dioxide; RYR1 - Ryanodine Receptor gene Key words: Anesthesia, General / methods; Dantrolene / therapeutic use; Diagnosis, Differential; Humans; Malignant Hyperthermia / diagnosis; Malignant Hyperthermia / etiology; Malignant Hyperthermia / physiopathology; Malignant Hyperthermia / therapy Citation: Victor R, Kelly R, Cockrill R, Katrivesis K, Nelson C, Rajan G. A rare case of late onset malignant hyperthermia. Anaesth. pain intensive care. 2022;26(4):546-550; DOI: 10.35975/apic.v26i4.1963 Received: November 19, 2021; Reviewed: April 25, 2022; Accepted: July 12. 2022